Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors

被引:65
作者
Hamby, JM [1 ]
Showalter, HDH [1 ]
机构
[1] Parke Davis Pharmaceut Res, Dept Chem, Ann Arbor, MI 48105 USA
关键词
angiogenesis; antiangiogenic; tyrosine kinase inhibitors; small molecules;
D O I
10.1016/S0163-7258(98)00053-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Angiogenesis is an exciting and promising new area of research. The concept that tumor cells are absolutely dependent upon neovascularization to grow and metastasize has opened the door to a multitude of new approaches and targets for developing anticancer therapies. These potential new antiangiogenic therapies offer the possibility for improved efficacy and reduced toxicity relative to conventional cancer treatments without the possibility of drug resistance. In particular, reports of small molecule inhibitors of tumor-promoted angiogenesis are appearing ever more frequently in the scientific literature. For this reason, the major focus of this review will be to cover small molecule inhibitors of tumor-promoted angiogenesis. The present review concentrates on selected literature, principally from mid-1996 to mid-1998, where there are sufficient biological data to support claims of antiangiogenic activities by small molecules. In addition, a historical background is presented and some of the important issues related to this field are (C) 1999 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:169 / 193
页数:25
相关论文
共 191 条
  • [31] Derbyshire EJ, 1997, TUMOUR ANGIOGENESIS, P343
  • [32] Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS Clinical Trial Group Study
    Dezube, BJ
    Von Roenn, JH
    Holden-Wiltse, J
    Cheung, TW
    Remick, SC
    Cooley, TP
    Moore, J
    Sommadossi, JP
    Shriver, SL
    Suckow, CW
    Gill, PS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1444 - 1449
  • [33] Dimitroff C. J., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P96
  • [34] EHRMANN RL, 1968, J NATL CANCER I, V41, P1329
  • [35] Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia
    Enholm, B
    Paavonen, K
    Ristimaki, A
    Kumar, V
    Gunji, Y
    Klefstrom, J
    Kivinen, L
    Laiho, M
    Olofsson, B
    Joukov, V
    Eriksson, U
    Alitalo, K
    [J]. ONCOGENE, 1997, 14 (20) : 2475 - 2483
  • [36] Ferrara N, 1997, TUMOUR ANGIOGENESIS, P185
  • [37] Figg WD, 1997, PHARMACOTHERAPY, V17, P91
  • [38] ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS
    FOLKMAN, J
    MERLER, E
    ABERNATHY, C
    WILLIAMS, G
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1971, 133 (02) : 275 - +
  • [39] ANGIOGENESIS INHIBITION AND TUMOR-REGRESSION CAUSED BY HEPARIN OR A HEPARIN FRAGMENT IN THE PRESENCE OF CORTISONE
    FOLKMAN, J
    LANGER, R
    LINHARDT, RJ
    HAUDENSCHILD, C
    TAYLOR, S
    [J]. SCIENCE, 1983, 221 (4612) : 719 - 725
  • [40] ANGIOGENIC FACTORS
    FOLKMAN, J
    KLAGSBRUN, M
    [J]. SCIENCE, 1987, 235 (4787) : 442 - 447